Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Bundle
Who's buying Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - and why - matters now more than ever: the company sits at a market capitalization of CNY 12.36 billion (as of December 12, 2025) while its stock trades in a 52‑week range of CNY 19.83-24.94, offering a picture of moderate volatility against an exceptionally low beta of 0.10 that appeals to risk‑averse portfolios; beneath the price action, trailing twelve‑month revenue of CNY 3.78 billion (TTM to Sept 30, 2025) and net income of CNY 799.61 million (a ~21.1% net margin) signal profitable, steady growth, and a 4.17% dividend yield with a CNY 0.90 per‑share cash payout adds tangible income appeal-factors that help explain why major holders like controlling shareholder Henan Lingrui Group (owning 21.48% as of Q3 2024) and institutional names such as BlackRock (12,800 shares reported as of March 31, 2025) are on the register; strategic moves like the January 2025 acquisition of a 90% stake in Yingu Pharmaceutical for approximately CNY 703.91 million further shape investor sentiment and raise the stakes for those tracking mid‑cap plays in China's pharmaceutical sector, so read on to see who's piling in, who's watching, and what those positions could mean for the stock's next chapter
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Who Invests in Henan Lingrui Pharmaceutical Co., Ltd. and Why?
Henan Lingrui Pharmaceutical presents a mix of attributes that attract distinct investor groups: stable revenue growth, high profitability, low market volatility, and a material cash dividend. Below are the primary investor types and the drivers behind their interest.- Institutional investors - Drawn to steady TTM revenue of CNY 3.78 billion (TTM ending 2025-09-30) and strong net income of CNY 799.61 million, offering scalable exposure to China's pharma sector.
- Income-focused investors - Attracted by a 4.17% dividend yield and a cash dividend of CNY 0.90 per share, providing predictable cash returns.
- Risk-averse investors - Favor the company's very low beta (0.10), which signals reduced correlation with broader market swings and lower volatility.
- Value and margin-seeking investors - Note the 21.1% net profit margin as evidence of efficient operations and attractive return on sales.
- Long-term growth investors - Interested in the company's 6.15% YoY revenue growth and market position within China's pharmaceutical landscape.
- Retail investors - May be enticed by dividend income and relatively narrow 52-week trading range, offering perceived stability.
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | CNY 12.36 billion | As of 2025-12-12 |
| 52-Week Range | CNY 19.83 - CNY 24.94 | Indicates moderate price fluctuation |
| Revenue (TTM) | CNY 3.78 billion | TTM ending 2025-09-30; +6.15% YoY |
| Net Income (TTM) | CNY 799.61 million | Strong absolute profitability |
| Net Profit Margin | 21.1% | Efficient cost control and pricing |
| Beta | 0.10 | Low volatility versus market |
| Dividend Yield | 4.17% | Cash dividend CNY 0.90 per share |
- Timing and tactical interest - Some traders use the 52-week range and low beta to implement conservative option or dividend-capture strategies.
- Portfolio allocation rationale - Henan Lingrui can serve as a defensive position within a broader equity portfolio due to high margins and low volatility.
- Link for deeper financial analysis - Breaking Down Henan Lingrui Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Institutional Ownership and Major Shareholders of Henan Lingrui Pharmaceutical Co., Ltd.
Henan Lingrui Pharmaceutical Co., Ltd. displays a concentrated ownership structure with a dominant strategic investor and measurable institutional interest from global asset managers. Key ownership and investor-profile datapoints point to a company attractive to investors prioritizing income, low volatility, and steady revenue growth.- Largest shareholder: Henan Lingrui Group - 21.48% stake (as of Q3 2024).
- Notable institutional holding: BlackRock - 12,800 shares (as of March 31, 2025).
- Market-cap change: +1.76% over the past 12 months (latest reported period).
- Revenue growth: +6.15% YoY for the TTM ending Sep 30, 2025.
- Volatility profile: Beta = 0.10 (low market sensitivity).
- Dividend profile: Dividend yield = 4.17%.
| Shareholder | Holding (%) / Shares | As of | Notes |
|---|---|---|---|
| Henan Lingrui Group | 21.48% | Q3 2024 | Largest strategic/controlling shareholder |
| BlackRock | 12,800 shares | Mar 31, 2025 | Global institutional investor - signals foreign/institutional interest |
| Metric | Value | Period |
|---|---|---|
| Market Capitalization Change | +1.76% | Past 12 months |
| Revenue Growth (YoY) | +6.15% | TTM ending Sep 30, 2025 |
| Beta | 0.10 | Latest |
| Dividend Yield | 4.17% | Latest |
- Why institutions buy: stable income via a 4.17% yield, low volatility (beta 0.10) for portfolio risk reduction, and modest revenue momentum (6.15% YoY TTM) that supports dividend sustainability.
- Why strategic/insider ownership matters: Henan Lingrui Group's 21.48% stake aligns management and shareholder incentives and can provide governance stability or block certain hostile moves.
- Significance of prominent holders: BlackRock's disclosed 12,800-share position (Mar 31, 2025) is a signaling event-large global managers tend to add scrutiny and liquidity even when absolute share counts are modest.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Key Investors and Their Impact on Henan Lingrui Pharmaceutical Co., Ltd.
Henan Lingrui Pharmaceutical's shareholder composition and measurable market metrics shape investor perceptions and strategic flexibility. Major holdings by the founding group, coupled with selective institutional interest and measurable operating and market indicators, create a profile attractive to both income-seeking and stability-minded investors.- Founding/strategic control: Henan Lingrui Group - 21.48% stake (third quarter 2024) - signals strong insider confidence and provides a stabilizing influence on corporate strategy and board decisions.
- Institutional endorsement: BlackRock - 12,800 shares as of March 31, 2025 - represents visible external validation that can enhance market credibility and attract follow-on institutional or retail interest.
- Market positioning: Market capitalization of CNY 12.36 billion (as of December 12, 2025) - places the company in the mid-cap pharmaceutical tier, balancing scale with growth potential.
| Metric | Value | Date / Period |
|---|---|---|
| Largest shareholder (Henan Lingrui Group) | 21.48% | Q3 2024 |
| BlackRock holdings | 12,800 shares | March 31, 2025 |
| Market capitalization | CNY 12.36 billion | December 12, 2025 |
| Revenue growth (YoY) | 6.15% | TTM ending September 30, 2025 |
| Beta (volatility) | 0.10 | Latest reported |
| Dividend yield | 4.17% | Latest reported |
- Governance and strategy: A 21.48% stake by Henan Lingrui Group provides the company with strategic continuity and the ability to pursue longer-term investments without constant shareholder turnover pressure.
- Perception and liquidity: Even modest BlackRock participation (12,800 shares) can serve as a signaling mechanism to the market - institutions often attract analyst attention and improve perceived liquidity and governance standards.
- Risk-return profile: Low beta (0.10) indicates substantially lower market sensitivity, making the stock appealing for risk-averse allocations or as a defensive holding within a healthcare sleeve.
- Income component: A 4.17% dividend yield combined with stable, modest revenue growth (6.15% YoY TTM Sep 30, 2025) positions the stock for investors prioritizing yield plus moderate growth.
- Mid-cap strategic fit: With CNY 12.36 billion market cap, Henan Lingrui fits portfolios targeting mid-cap pharmaceuticals that can offer both operational scale and room for expansion or M&A-driven upside.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Market Impact and Investor Sentiment
Henan Lingrui Pharmaceutical's market capitalization of CNY 12.36 billion as of December 12, 2025, positions the company as a meaningful mid-cap participant in China's pharmaceutical sector, with the size to influence peer valuation benchmarks and sector ETFs. Its revenue growth of 6.15% year-over-year for the TTM ending September 30, 2025, combined with a notably low beta of 0.10, frames the stock as a stable earnings grower that can attract defensive allocations in equity portfolios. The 4.17% dividend yield further strengthens the case for income-focused investors, while strategic M&A activity-most prominently the January 2025 acquisition of a 90% stake in Yingu Pharmaceutical Co., Ltd. for approximately CNY 703.91 million-signals management's intent to expand capabilities and revenue streams, which can shift sentiment among both growth and value investors.- Institutional interest: pension funds and insurance companies favoring low-volatility, dividend-paying names.
- Retail investors: drawn by yield and perceived safety due to low beta and steady revenue growth.
- Specialized healthcare funds: monitoring the Yingu acquisition for pipeline or production synergies.
- Event-driven investors: watching integration milestones and any margin uplift post-acquisition.
| Metric | Value |
|---|---|
| Market Capitalization (12-Dec-2025) | CNY 12.36 billion |
| Revenue Growth (TTM ended 30-Sep-2025, YoY) | 6.15% |
| Beta | 0.10 |
| Dividend Yield | 4.17% |
| Notable Acquisition | 90% stake in Yingu Pharmaceutical Co., Ltd. (Jan 2025) |
| Acquisition Consideration | Approx. CNY 703.91 million |
- Stability narrative - low beta and yield create a defensive profile during market volatility.
- Income narrative - 4.17% yield appeals in low-rate or uncertain-rate environments.
- Growth through acquisition - the Yingu deal is perceived as a catalyst for revenue diversification and potential margin expansion.
- Risk considerations - integration execution, regulatory oversight in pharma, and competitive pressure remain watch points for cautious investors.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.